Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Billin

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Toxicology|December 7, 2007
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell linesElizabeth E Girroir, Holly E Hollingshead, Andrew N Billin, et al.
Plos One|March 4, 2014
Human and mouse skeletal muscle stem cells: convergent and divergent mechanisms of myogenesisAkshay Bareja, Jason A Holt, Guizhen Luo, et al.
Diabetes, Obesity & Metabolism|May 15, 2025
Antidiabetic and lipid-lowering medication use inversely linked with serum biomarkers of liver fibrosisJun Wang, Dora Ding, Xiaorong Shao, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 4, 2011
Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genesJanine M Lamonica, Wulan Deng, Stephan Kadauke, et al.
Carcinogenesis|August 19, 2007
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell linesHolly E Hollingshead, Renee L Killins, Michael G Borland, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 18, 2006
Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonistDennis L Sprecher, Christine Massien, Greg Pearce, et al.
Molecular Endocrinology (Baltimore, Md.)|November 3, 2007
Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonistBarry G Shearer, David J Steger, James M Way, et al.
Journal of Lipid Research|February 3, 2023
Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrateMohamad Dandan, Julia Han, Sabrina Mann, et al.
Clinical Pharmacology and Therapeutics|October 8, 2021
Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RAAmy Meng, Rita Humeniuk, Juliane M Jürgensmeier, et al.
ACS Chemical Biology|December 24, 2015
Discovery of Novel Small Molecules that Activate Satellite Cell Proliferation and Enhance Repair of Damaged MuscleAndrew N Billin, Marcus Bantscheff, Gerard Drewes, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Toxicology|December 7, 2007
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell linesElizabeth E Girroir, Holly E Hollingshead, Andrew N Billin, et al.
Plos One|March 4, 2014
Human and mouse skeletal muscle stem cells: convergent and divergent mechanisms of myogenesisAkshay Bareja, Jason A Holt, Guizhen Luo, et al.
Diabetes, Obesity & Metabolism|May 15, 2025
Antidiabetic and lipid-lowering medication use inversely linked with serum biomarkers of liver fibrosisJun Wang, Dora Ding, Xiaorong Shao, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 4, 2011
Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genesJanine M Lamonica, Wulan Deng, Stephan Kadauke, et al.
Carcinogenesis|August 19, 2007
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell linesHolly E Hollingshead, Renee L Killins, Michael G Borland, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 18, 2006
Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonistDennis L Sprecher, Christine Massien, Greg Pearce, et al.
Molecular Endocrinology (Baltimore, Md.)|November 3, 2007
Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonistBarry G Shearer, David J Steger, James M Way, et al.
Journal of Lipid Research|February 3, 2023
Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrateMohamad Dandan, Julia Han, Sabrina Mann, et al.
Clinical Pharmacology and Therapeutics|October 8, 2021
Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RAAmy Meng, Rita Humeniuk, Juliane M Jürgensmeier, et al.
ACS Chemical Biology|December 24, 2015
Discovery of Novel Small Molecules that Activate Satellite Cell Proliferation and Enhance Repair of Damaged MuscleAndrew N Billin, Marcus Bantscheff, Gerard Drewes, et al.
Pageof 6